NCT06447727

Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM

Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of Colorectal Cancer Liver Metastasis

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 30 (estimated)
• Sponsor: Zhongda Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To observe the PFS of yttrium \[90Y\] microsphere injection combined with FOLFIRI and bevacizumab in second-line treatment of CRLM.

Detailed description

This study is a prospective, multicenter, observational, cohort study to observe the efficacy and safety of selective internal radiation therapy (SIRT) with yttrium \[90Y\] microsphere injection combined with FOLFIRI and bevacizumab as second-line therapy in patients with colorectal cancer liver metastases.

Conditions

• Colorectal Cancer Metastatic

Interventions

Type	Name	Description
DRUG	SIRT with Yttrium-90 Microspheres	Selective Internal Radiation Therapy (SIRT) with Yttrium-90 \[90Y\] Microspheres Injection
DRUG	FOLFIRI and Bevacizumab	FOLFIRI and Bevacizumab

Timeline

• Start date: 2024-05-20
• Primary completion: 2025-11-30
• Completion: 2025-11-30
• First posted: 2024-06-07
• Last updated: 2024-06-07

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study